Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
CD16, the type III receptor for IgG, is expressed on neutrophils, natural killer cells, and some T lymphocytes, mast cells, and activated monocytes but not on cells of the B-lymphocyte lineage including plasma cells. It is also produced in a soluble form found in serum. We analyzed sera from 165 multiple-myeloma patients, 29 patients with monoclonal gammopathies of unknown significance, and 20 normal disease-free donors. We found that the level of soluble CD16 was significantly decreased in sera from patients with multiple myeloma compared to sera from healthy and monoclonal gammopathies of unknown significance donors (P = 0.0001). In addition, a stage-dependent decrease in soluble CD16 was observed, with a highly significant difference (P = 0.004) between stage I and stage II+III myeloma patients. The correlation between the myeloma stage and the serum level of soluble CD16, which is related to the host response, was found to be more sensitive than that of beta 2-microglobulin, which reflects the tumor burden. The concomitant evaluation of the serum levels of these two markers allows better staging and therefore has a more precise prognostic value.
Mathiot
C
C
Laboratoires d'Immunologie et d'Hématologie, INSERM U, Paris, France.
Teillaud
J L
JL
Elmalek
M
M
Mosseri
V
V
Euller-Ziegler
L
L
Daragon
A
A
Grosbois
B
B
Michaux
J L
JL
Facon
T
T
Bernard
J F
JF
D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood* / Q000276:immunology / Q000473:pathology; D009367:Neoplasm Staging; D010265:Paraproteinemias / Q000097:blood / Q000276:immunology; D017452:Receptors, IgG / Q000032:analysis*; D012995:Solubility; D001613:beta 2-Microglobulin / Q000032:analysis
D014408:Biomarkers, Tumor; D017452:Receptors, IgG; D001613:beta 2-Microglobulin